Evaluating the Impact of Uveitis on Visual Field Progression Using Large-Scale Real-World Data.
Liu Xiaoxuan, Kelly Stephen R, Montesano Giovanni, Bryan Susan R, Barry Robert J, Keane Pearse A, Denniston Alastair K, Crabb David P
AI Summary
This study found glaucoma patients with uveitis experience significantly faster visual field loss than those with POAG. This highlights uveitic glaucoma as a high-risk group needing early, targeted intervention.
Abstract
Purpose
To compare rates of visual field (VF) loss in uveitis patients with glaucoma against patients with primary open-angle glaucoma (POAG) and explore the association between intraocular pressure (IOP) and rate of VF loss.
Design
Retrospective cohort study.
Methods
Anonymized VFs and IOP measurements extracted from the electronic medical records of 5 regionally different glaucoma clinics in England. A total of 205 eyes with diagnosis of uveitis plus glaucoma were compared with 4600 eyes with POAG only. Minimum inclusion criteria were ≥4 visits within a 4-year window. Relative risk (RR) of being a "rapid progressor" (mean deviation [MD] loss ≥1.5 dB/year) was calculated. A mixed-effects model (MEM) and a pointwise VF progression analysis of pattern deviation were used to confirm differences between the groups. Longitudinal IOP mean, range, and variability were compared with rate of VF progression.
Results
Median (interquartile range) baseline MD in the uveitis and POAG groups was -3.8 (-8.7, -1.5) dB and -3.1 (-6.6, -1.2) dB, respectively. The uveitis and POAG groups had 23 of 205 (11%) and 331 of 4600 (7%) "rapidly progressing" eyes, respectively. Age-adjusted RR for "rapid progression" in uveitic vs POAG eyes was 1.9 (95% confidence interval: 1.8-2.0). The MEM confirmed that uveitic eyes (-0.49 dB/year) showed higher rates of VF progression than the POAG group (-0.37 dB/year; P < .01). IOP range and variability were higher in the "rapidly progressing" uveitic eyes.
Conclusions
Our analysis suggests that VF loss occurs faster in glaucoma patients with uveitis than those without uveitis. The risk of progressing rapidly in glaucoma with uveitis is almost double than in those without uveitis. Early identification of "rapid progressors" may enable targeted intervention to preserve visual function in this high-risk group.
MeSH Terms
Shields Classification
Key Concepts5
In a retrospective cohort study of 205 eyes with uveitis plus glaucoma and 4600 eyes with primary open-angle glaucoma (POAG) from 5 regionally different glaucoma clinics in England, uveitic eyes (-0.49 dB/year) showed higher rates of visual field (VF) progression than the POAG group (-0.37 dB/year; P < .01).
In a retrospective cohort study of 205 eyes with uveitis plus glaucoma and 4600 eyes with primary open-angle glaucoma (POAG), the age-adjusted relative risk (RR) for "rapid progression" (mean deviation [MD] loss ≥1.5 dB/year) in uveitic vs POAG eyes was 1.9 (95% confidence interval: 1.8-2.0).
In a retrospective cohort study of 205 eyes with uveitis plus glaucoma and 4600 eyes with primary open-angle glaucoma (POAG), the uveitis group had 23 of 205 (11%) "rapidly progressing" eyes (mean deviation [MD] loss ≥1.5 dB/year) compared to 331 of 4600 (7%) in the POAG group.
In a retrospective cohort study comparing uveitis patients with glaucoma to patients with primary open-angle glaucoma (POAG), intraocular pressure (IOP) range and variability were higher in the "rapidly progressing" uveitic eyes.
A retrospective cohort study compared rates of visual field (VF) loss in 205 eyes with uveitis plus glaucoma against 4600 eyes with primary open-angle glaucoma (POAG) and explored the association between intraocular pressure (IOP) and rate of VF loss.
Related Articles5
Lens-corrected visual field sensitivity and diabetes.
Observational StudyFunctional and structural change in diabetic eyes. Interim results from an ongoing longitudinal prospective study.
Cohort StudyIs Posner Schlossman syndrome benign?
Case SeriesVisual Field Progression Rates in Glaucoma: Frontloaded Versus Clinical Standard (Nonfrontloaded) SITA-Faster.
Observational StudyEndpoints and Design for Clinical Trials in USH2A-Related Retinal Degeneration: Results and Recommendations From the RUSH2A Natural History Study.
Clinical TrialIs this article assigned to the wrong chapter(s)? Let us know.